Chronic lymphocytic leukaemia: trials for referral
328 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Chronic lymphocytic leukaemia·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
328 trials shown
Phase 22 sites
RecruitingUnited States
NCT07582159
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
Pre-treatment window Registry sentence: “No prior treatment for CLL/SLL, except steroids and/or rituximab to treat autoimmune complications”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3106 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, Chile
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Merck Sharp & Dohme LLC
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07796373
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
National Heart, Lung, and Blood Institute (NHLBI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 131 sites
RecruitingAustralia, China, Germany, Spain, France, United Kingdom
NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 3633 sites
RecruitingCanada, United States
NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 142 sites
By invitation onlyAustralia, Belgium, Denmark, Spain, France, United Kingdom
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 2129 sites
RecruitingAustralia, Belgium, Canada, Czechia, Germany, Denmark
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Pre-treatment window Registry sentence: “Part 2: Have received no prior treatment for CLL/SLL”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 27 sites
RecruitingColombia, Israel
NCT07709000
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Merck Sharp & Dohme LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 450 sites
RecruitingAustria, Australia, Belgium, Canada, China, Czechia
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 243 sites
RecruitingFrance, United Kingdom, Italy, Poland, United States
NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3261 sites
RecruitingUnited States
NCT07321652
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Alliance for Clinical Trials in Oncology
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 1/29 sites
RecruitingUnited States
NCT07520006
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Pre-treatment window Registry sentence: “For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06967610
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
M.D. Anderson Cancer Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07891468
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
University of Pennsylvania
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT04016129
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 24 sites
RecruitingUnited States
NCT06520098
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06839053
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Pre-treatment window Registry sentence: “For the treatment-naïve cohort, patients should have no prior treatment for CLL/SLL (other than 1 aborted regimen \< 2 weeks in duration and \> 4 weeks before enrollment)”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/24 sites
RecruitingUnited States
NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07194980
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 119 sites
RecruitingUnited States
NCT04301076
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Patients must have histologically or cytologically confirmed CD2+, CD3+, or CD4+ acute, lymphoma or poor-risk chronic subtypes of ATLL including previously untreated or previously treated individuals who have received no more than 1 previous cycle of EPOCH, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE)”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07254793
Prophylactic DLI-X for Leukemia Relapse After HCT
University of Arizona
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07508995
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “Patients with a diagnosis of previously untreated CLL/SLL meeting iwCLL 2018 indication for treatment (Note: patients who receive steroids and/or CD20 monoclonal antibody for cytoreduction in those patients presenting with significantly elevated WBC count or significant adenopathy/organomegaly and those who previously received steroids/CD20 monoclonal antibody for immune cytopenias are eligible to enroll; Washout of 4 weeks applies for CD20 monoclonal antibody and dose of prednisone (or equivalent) should be less than 20mg/day by day 1 of study initiation)”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingChina
NCT04807881
Phase Ib Clinical Study of Keynatinib
Medolution Ltd.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 1/259 sites
RecruitingAustralia, China, Czechia, Germany, Denmark, Spain
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
AstraZeneca
Pre-treatment window Registry sentence: “Histologically confirmed diagnosis of previously untreated large B-cell Lymphoma (LBCL) per WHO 2022.”
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 2121 sites
RecruitingArgentina, Australia, Brazil, Canada, Switzerland, China
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive”
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07899398
A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL
German CLL Study Group
Pre-treatment window Registry sentence: “Hasve documented treatment-naïve CLL or small lymphocytic lymphoma (SLL) according to iwCLL 2018 criteria4”
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06013423
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingUnited States
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States185 open trials
- France49 open trials
- China48 open trials
- Italy45 open trials
- Spain42 open trials
- Germany37 open trials
- Poland36 open trials
- United Kingdom33 open trials
- Australia28 open trials
- Canada22 open trials
- Czechia19 open trials
- Belgium17 open trials
- South Korea15 open trials
- Brazil13 open trials
- Denmark13 open trials
- Japan12 open trials
- Netherlands12 open trials
- Israel9 open trials
- Türkiye9 open trials
- Romania9 open trials
- Austria9 open trials
- Sweden9 open trials
- Hungary8 open trials
- Taiwan6 open trials
- Greece6 open trials
- Switzerland6 open trials
- New Zealand5 open trials
- Argentina5 open trials
- Ukraine5 open trials
- Ireland5 open trials
- Moldova4 open trials
- Bulgaria4 open trials
- Chile3 open trials
- Georgia3 open trials
- Mexico2 open trials
- South Africa2 open trials
- Colombia2 open trials
- Puerto Rico2 open trials
- Slovakia2 open trials
- Croatia2 open trials
- Serbia2 open trials
- Belarus2 open trials
- Russia2 open trials
- Norway2 open trials
- Finland2 open trials
- Bosnia and Herzegovina1 open trial
- Singapore1 open trial
- India1 open trial
- Hong Kong1 open trial
- Portugal1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Turin, Italy
1 trial · 8 publications · ROR
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, Italy
16 trials · 9 publications · ROR
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
Catania, Italy
4 trials · 7 publications · ROR
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
36 trials · 17 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
15 trials · 7 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Recruiting → Not yet recruiting
NCT07860775 · Phase 2 · Denmark, Netherlands, Sweden
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.govOpened for recruitment
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478 · Phase 3 · Czechia, Germany, Spain, France, Italy, Poland
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07082452 · Phase 3 · Spain, France
Source: ClinicalTrials.govOpened for recruitment
NCT06428019 · Phase 3 · Australia, Spain, France, United Kingdom, Greece, Puerto Rico
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 3
NCT06428019 · Phase 3 · Australia, Spain, France, United Kingdom, Greece, Puerto Rico
Source: ClinicalTrials.govClosed for recruitment
NCT06291220 · Phase 1 · Australia, Germany, Israel, Italy, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05688475 · Phase 1 · France, Japan, Netherlands, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05512390 · Phase 1 · Australia, Canada, Spain, France, Israel, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05424822 · Phase 1 · Australia, China, Denmark, France, Israel, Japan
Source: ClinicalTrials.govClosed for recruitment
NCT05458297 · Phase 2 · Brazil, Canada, Chile, China, Czechia, Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Belimumab in Patients with Chronic Lymphocytic Leukemia
NCT05069051 · Phase 2 · Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681 · Phase 3 · Australia, Belgium, Brazil, Canada, Chile, Colombia
Source: ClinicalTrials.govOpened for recruitment
NCT06291220 · Phase 1 · Australia, Germany, Israel, Italy, United States
Source: ClinicalTrials.govClosed for recruitment
NCT06428019 · Phase 3 · Australia, Spain, France, United Kingdom, Greece, Puerto Rico
Source: ClinicalTrials.govOpened for recruitment
NCT07860775 · Phase 2 · Denmark, Netherlands, Sweden
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
NCT07342478 · Phase 3 · Czechia, Germany, Spain, France, Italy, Poland
Source: ClinicalTrials.gov
Show more
Opened for recruitment
NCT05458297 · Phase 2 · Brazil, Canada, Chile, China, Czechia, Germany
Source: ClinicalTrials.govOpened for recruitment
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
NCT07709000 · Phase 2 · Colombia, Israel
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775 · Phase 1/2 · Germany
Source: ClinicalTrials.govPhase changed: No phase → Phase 1
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 8 Sept 2026
Completed93 participants
NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Early Phase 1Ended 28 Aug 2026
Stopped early21 participants
NCT06636175
64Cu-LLP2A for Imaging Hematologic Malignancies
Reason given: Loss of further funding
No phaseEnded 14 Aug 2026
Completed70 participants
NCT07882069
Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia
No phaseEnded 4 Aug 2026
No phaseEnded 31 Jul 2026
Stopped early200 participants
NCT03050190
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
No reason given in the registry.
Phase 1/2Ended 31 Jul 2026
Stopped early100 participants
NCT03125577
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
No reason given in the registry.
Phase 2Ended 7 Jul 2026
Completed47 participants
NCT05672355
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Phase 1/2Ended 1 Jul 2026
Completed55 participants
NCT03534323
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Phase 2Ended Jun 2026
Withdrawn before start0 participants
NCT04660045
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Reason given: Company supplying drug/funding ceased support.
No phaseEnded 17 Jun 2026
Completed269 participants
NCT03415035
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
Phase 1Ended 8 Jun 2026
Stopped early51 participants
NCT05828589
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Reason given: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.
Phase 1Ended 26 May 2026
Completed15 participants
NCT03447808
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
No phaseEnded 26 May 2026
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 1Ended 20 Apr 2026
No phaseEnded 20 Mar 2026
Completed45 participants
NCT05517265
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
Phase 1Ended 2 Mar 2026
No phaseEnded 28 Feb 2026
Phase 2Ended 10 Feb 2026
Completed31 participants
2024-514686-19-00
Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1Ended 10 Feb 2026
Stopped early9 participants
NCT06761586
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Reason given: Patient recruitment problems
Show more
Phase 2Ended 2 Feb 2026
Phase 2Ended 27 Jan 2026
Completed42 participants
NCT03609593
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 15 Jan 2026
Completed35 participants
NCT02649387
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Phase 2Ended 9 Jan 2026
Phase 2Ended 9 Jan 2026
Completed15 participants
NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2Ended 5 Jan 2026
Phase 2Ended 5 Jan 2026
No phaseEnded Dec 2025
Withdrawn before start0 participants
NCT02298816
B-Cell Hematologic Malignancy Vaccination Registry
Reason given: No patients enrolled
Phase 1/2Ended Dec 2025
Withdrawn before start0 participants
NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given: PI has left IU with no plan to initiate study at IU
Phase 2Ended 29 Dec 2025
Completed87 participants
NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase 1/2Ended 23 Dec 2025
Completed803 participants
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. · Cancer chemotherapy and pharmacology, 2026
- Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. · The Lancet. Haematology, 2026
- Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. · American journal of hematology, 2026
Phase 1Ended 19 Dec 2025
Phase 2Ended 17 Dec 2025
Completed230 participants
NCT03226301
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups
Phase 2Ended 30 Nov 2025
Phase 2Ended 30 Nov 2025
Stopped early30 participants
NCT03708003
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Reason given: The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.
Phase 3Ended 4 Nov 2025
Completed552 participants
NCT04008706
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Phase 2Ended 31 Oct 2025
Completed48 participants
NCT02337829
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Phase 2Ended Oct 2025
Withdrawn before start0 participants
NCT05465876
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Reason given: Funding pulled
Phase 1/2Ended 31 Oct 2025
Withdrawn before start0 participants
NCT05570188
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Reason given: The PI decides to stop.
Phase 1/2Ended 27 Oct 2025
Completed161 participants
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Phase 1Ended 22 Oct 2025
Completed69 participants
NCT02296918
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase 3Ended 17 Oct 2025
Completed21 participants
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Phase 2Ended 9 Oct 2025
Phase 1/2Ended 6 Oct 2025
Stopped early3 participants
NCT05317936
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Reason given: \<75% participation
Phase 1Ended 6 Oct 2025
Completed16 participants
NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Phase 3Ended 19 Sept 2025
Phase 1Ended 9 Sept 2025
Completed147 participants
NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 1/2Ended 1 Sept 2025
Completed713 participants
NCT02500407
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. · American journal of hematology, 2026
- Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation. · Blood advances, 2026
Phase 3Ended 27 Aug 2025
Completed445 participants
NCT02242942
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase 1/2Ended 25 Aug 2025
Completed25 participants
2022-501686-47-00
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2Ended 21 Aug 2025
Completed70 participants
2024-511048-22-00
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL)
Phase 1Ended 21 Aug 2025
Completed200 participants
NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
No phaseEnded 20 Aug 2025
Completed67 participants
NCT05665374
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
No phaseEnded 18 Aug 2025
Completed14 participants
NCT04178317
A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice
Phase 1Ended 13 Aug 2025
Stopped early9 participants
NCT05515406
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Reason given: The study was terminated due to a strategic decision to discontinue development.
Phase 1Ended 5 Aug 2025
Completed13 participants
NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Phase 1Ended 1 Aug 2025
Completed50 participants
NCT02996773
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
No phaseEnded Jul 2025
Completed10 participants
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Phase 1Ended Jul 2025
Withdrawn before start0 participants
NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given: Medigene transfered all rights to a new Sponsor
Not medical advice. fetched 10 Nov 2026